Financial results - SWIXX BIOPHARMA S.R.L.

Financial Summary - Swixx Biopharma S.r.l.
Unique identification code: 39625420
Registration number: J2018010115407
Nace: 4646
Sales - Ron
3.858.635
Net Profit - Ron
208.759
Employees
30
Open Account
Company Swixx Biopharma S.r.l. with Fiscal Code 39625420 recorded a turnover of 2024 of 3.858.635, with a net profit of 208.759 and having an average number of employees of 30. The company operates in the field of Comerţ cu ridicata al produselor farmaceutice și medicale having the NACE code 4646.
Sales - Ron

Sales, Profit, Employees, Total Income, Financial Results - Swixx Biopharma S.r.l.

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Sales - EUR - - - 0 57.738 199.130 901.149 1.537.824 2.654.769 3.858.635
Total Income - EUR - - - 24 59.010 200.956 903.246 1.539.367 2.657.865 3.863.209
Total Expenses - EUR - - - 2.008 56.562 191.783 844.610 1.426.505 2.533.434 3.593.556
Gross Profit/Loss - EUR - - - -1.984 2.448 9.173 58.636 112.862 124.431 269.653
Net Profit/Loss - EUR - - - -1.984 1.871 7.315 52.508 75.560 58.407 208.759
Employees - - - 0 1 2 15 18 28 30
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded. In the last year of activity, the sales increased by 46.2%, from 2.654.769 euro in the year 2023, to 3.858.635 euro in 2024. The Net Profit increased by 150.679 euro, from 58.407 euro in 2023, to 208.759 in the last year.
Sales - Ron
Net Profit - Ron
Employees

Check the financial reports for the company - Swixx Biopharma S.r.l.

Rating financiar

Financial Rating -
SWIXX BIOPHARMA S.R.L.

See the company's note based on the submitted financial data, relative to the industry of which it is a part.

Financial Rating
Limite de plata

Payment Limits -
Swixx Biopharma S.r.l.

See the company's payment capacity for situations in which you conclude contracts with payment terms.

Check Payment Limits
Probabilitate de insolventa

Prob. of insolvency -
Swixx Biopharma S.r.l.

It determines the risk of insolvency based on the submitted accounting balance.

Insolvency Probability
Rapoarte financiare

Financial Reports -
Swixx Biopharma S.r.l.

Check all the financial reports of the company and know the risks in collaboration with it.

Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.

Debts, Equity, Inventories, Receivables, Accounts, Assets - Swixx Biopharma S.r.l. - CUI 39625420

2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Fixed Assets - - - 0 1.274 2.058 24.047 52.368 165.226 213.283
Current Assets - - - 8.026 20.841 37.439 156.675 335.417 910.889 957.385
Inventories - - - 0 0 0 0 0 277.420 158.118
Receivables - - - 0 9.395 23.957 124.382 98.287 263.686 382.843
Cash - - - 8.026 11.446 13.482 32.293 237.130 369.783 416.424
Shareholders Funds - - - -1.941 -33 7.282 59.628 135.373 193.369 401.047
Social Capital - - - 43 42 41 40 41 40 40
Debts - - - 10.677 22.864 32.930 132.655 265.500 901.287 770.266
Income in Advance - - - 0 0 0 0 5.167 5.276 3.389
Exchange rate - RON 4.9743 4.9465 4.9315 4.9468 4.8371 4.7454 4.6535 4.5681 4.4908 4.445
Main CAEN "4646 - 4646"
CAEN Financial Year 4646
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of 957.385 euro in 2024 which includes Inventories of 158.118 euro, Receivables of 382.843 euro and cash availability of 416.424 euro.
The company's Equity was valued at 401.047 euro, while total Liabilities amounted to 770.266 euro. Equity increased by 208.759 euro, from 193.369 euro in 2023, to 401.047 in 2024. The Debt Ratio was 65.6% in the year 2024.

Risk Reports Prices

Reviews - Swixx Biopharma S.r.l.

Comments - Swixx Biopharma S.r.l.

Similar services useful for checking companies and business development.

SellNet

Get the contact details for any company and get in touch with it.

Sectoral Studies

Knows the market and develops its own development strategies according to sectorial data.

Databases

Export in excel files the data of the companies selected according to the desired criteria.

Import - Export

Find importers and exporters according to the type of activity and the countries in which they carry it out.

Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.